Guardant Health Inc
GH49.540USD
-0.960-1.90%
Handelsschluss 07/07, 16:00（ET）Kurse um 15 Minuten verzögert
6.13BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Guardant Health Inc Unternehmen
Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
Unternehmensinformationen
BörsenkürzelGH
Name des UnternehmensGuardant Health Inc
IPO-datumOct 04, 2018
Gegründet am2011
CEODr. Amirali Talasaz, Ph.D.
Anzahl der mitarbeiter1999
WertpapierartOrdinary Share
GeschäftsjahresendeOct 04
Addresse3100 Hanover Street
StadtPALO ALTO
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl94304
Telefon18556988887
Websitehttps://guardanthealth.com/
BörsenkürzelGH
IPO-datumOct 04, 2018
Gegründet am2011
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Helmy A. Eltoukhy, Ph.D.
Dr. Helmy A. Eltoukhy, Ph.D.
Chairperson of the Board, Co-Chief Executive Officer
Chairperson of the Board, Co-Chief Executive Officer
2.75M
+0.43%
Dr. Amirali Talasaz, Ph.D.
Dr. Amirali Talasaz, Ph.D.
Co-Chief Executive Officer, Director
Co-Chief Executive Officer, Director
2.50M
-3.40%
Dr. Darya Chudova
Dr. Darya Chudova
Chief Technology Officer
Chief Technology Officer
80.44K
+1.88%
Mr. John Gomes Saia
Mr. John Gomes Saia
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
44.82K
+2.88%
Mr. Craig Eagle, M.D.
Mr. Craig Eagle, M.D.
Chief Medical Officer
Chief Medical Officer
36.79K
+4.75%
Ms. Vijaya V. Gadde
Ms. Vijaya V. Gadde
Independent Director
Independent Director
24.31K
+37.83%
Ms. Myrtle Stephens Potter
Ms. Myrtle Stephens Potter
Independent Director
Independent Director
18.15K
+29.09%
Mr. Kumud Kalia
Mr. Kumud Kalia
Chief Information Officer
Chief Information Officer
17.82K
+8.04%
Ms. Meghan V. Joyce
Ms. Meghan V. Joyce
Independent Director
Independent Director
11.15K
+42.11%
Mr. Musa Tariq
Mr. Musa Tariq
Independent Director
Independent Director
7.19K
+106.67%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Helmy A. Eltoukhy, Ph.D.
Dr. Helmy A. Eltoukhy, Ph.D.
Chairperson of the Board, Co-Chief Executive Officer
Chairperson of the Board, Co-Chief Executive Officer
2.75M
+0.43%
Dr. Amirali Talasaz, Ph.D.
Dr. Amirali Talasaz, Ph.D.
Co-Chief Executive Officer, Director
Co-Chief Executive Officer, Director
2.50M
-3.40%
Dr. Darya Chudova
Dr. Darya Chudova
Chief Technology Officer
Chief Technology Officer
80.44K
+1.88%
Mr. John Gomes Saia
Mr. John Gomes Saia
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
44.82K
+2.88%
Mr. Craig Eagle, M.D.
Mr. Craig Eagle, M.D.
Chief Medical Officer
Chief Medical Officer
36.79K
+4.75%
Ms. Vijaya V. Gadde
Ms. Vijaya V. Gadde
Independent Director
Independent Director
24.31K
+37.83%
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Oncology
150.56M
74.00%
Biopharma and data
45.38M
22.30%
Screening
5.68M
2.79%
Licensing and other
1.86M
0.91%
Nach RegionUSD
Name
Umsatz
Anteil
United States
193.61M
95.15%
International
9.86M
4.85%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Oncology
150.56M
74.00%
Biopharma and data
45.38M
22.30%
Screening
5.68M
2.79%
Licensing and other
1.86M
0.91%
Aktionärsstatistik
Aktualisiert: Sat, Jun 21
Aktualisiert: Sat, Jun 21
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
9.73%
BlackRock Institutional Trust Company, N.A.
6.95%
Deep Track Capital LP
4.39%
Capital International Investors
4.16%
Baillie Gifford & Co.
4.09%
Other
70.69%
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
9.73%
BlackRock Institutional Trust Company, N.A.
6.95%
Deep Track Capital LP
4.39%
Capital International Investors
4.16%
Baillie Gifford & Co.
4.09%
Other
70.69%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
38.09%
Investment Advisor/Hedge Fund
33.25%
Hedge Fund
21.67%
Individual Investor
4.57%
Research Firm
2.22%
Bank and Trust
1.82%
Sovereign Wealth Fund
1.81%
Pension Fund
1.28%
Insurance Company
0.03%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
741
129.90M
104.85%
-16.16M
2025Q1
783
130.34M
105.23%
-16.59M
2024Q4
746
130.16M
105.47%
-20.09M
2024Q3
780
137.29M
111.53%
-9.70M
2024Q2
801
127.50M
103.74%
-18.45M
2024Q1
826
124.00M
101.88%
-12.71M
2023Q4
856
120.18M
99.30%
-14.26M
2023Q3
867
117.78M
100.31%
-19.15M
2023Q2
890
119.83M
102.55%
+840.96K
2023Q1
908
101.46M
98.78%
-16.37M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
12.05M
9.73%
+28.83K
+0.24%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
8.61M
6.95%
-284.70K
-3.20%
Mar 31, 2025
Deep Track Capital LP
5.44M
4.39%
-975.85K
-15.20%
Mar 31, 2025
Capital International Investors
5.15M
4.16%
+674.48K
+15.08%
Mar 31, 2025
Baillie Gifford & Co.
5.06M
4.09%
-388.09K
-7.12%
Mar 31, 2025
Cadian Capital Management LP
4.60M
3.71%
-626.48K
-12.00%
Mar 31, 2025
Two Sigma Investments, LP
4.19M
3.38%
-12.65K
-0.30%
Mar 31, 2025
Citadel Advisors LLC
3.60M
2.9%
+2.12M
+142.72%
Mar 31, 2025
Eventide Asset Management, LLC
3.57M
2.88%
-241.20K
-6.33%
Mar 31, 2025
Capital Research Global Investors
2.93M
2.37%
+190.45K
+6.95%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sun, Jul 6
Aktualisiert: Sun, Jul 6
Name
Anteil
ARK Genomic Revolution ETF
6.11%
Global X Genomics & Biotechnology ETF
3.8%
Invesco Dorsey Wright Healthcare Momentum ETF
3.24%
Franklin Genomic Advancements ETF
2.43%
First Trust Nasdaq Lux Digi Health Solutions ETF
2.21%
ROBO Global Healthcare Technology & Innovation ETF
2.12%
Alger Mid Cap 40 ETF
1.85%
SPDR S&P Health Care Services ETF
1.82%
BNY Mellon Innovators ETF
1.39%
iShares Health Innovation Active ETF
1.23%
Mehr Anzeigen
ARK Genomic Revolution ETF
Anteil6.11%
Global X Genomics & Biotechnology ETF
Anteil3.8%
Invesco Dorsey Wright Healthcare Momentum ETF
Anteil3.24%
Franklin Genomic Advancements ETF
Anteil2.43%
First Trust Nasdaq Lux Digi Health Solutions ETF
Anteil2.21%
ROBO Global Healthcare Technology & Innovation ETF
Anteil2.12%
Alger Mid Cap 40 ETF
Anteil1.85%
SPDR S&P Health Care Services ETF
Anteil1.82%
BNY Mellon Innovators ETF
Anteil1.39%
iShares Health Innovation Active ETF
Anteil1.23%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
